1. Crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan.
2. The crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan of claim 1, wherein the crystals produce distinct peaks in a X-ray diffraction measurement having a half-value width below 2\xb0 measured at the reflection angle 2 theta using CuK\u03b1 radiation.
3. The crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan of claim 1, wherein the crystalline material is crystal modification 1 (polymorphic form F).
4. The crystal modification 1 (polymorphic form F) of the mono sodium salt of D-isoglutamyl-D-tryptophan of claim 3, having a XRPD pattern as shown in FIG. 2.
5. The crystal modification 1 (polymorphic form F) of the mono sodium salt of D-isoglutamyl-D-tryptophan of claim 3, having an XRPD pattern comprising peaks, in terms of 2\u03b8, at: 9.23\xb10.20, 9.91\xb10.20, 12.41\xb10.20, 13.76\xb10.20, 14.87\xb10.20, 15.75\xb10.20, 17.88\xb10.20, 18.78\xb10.20, 19.57\xb10.20, 19.84\xb10.20, 20.31\xb10.20, 21.32\xb10.20, 21.55\xb10.20, 22.95\xb10.20, 23.45\xb10.20, 24.34\xb10.20, 24.96\xb10.20, 27.49\xb10.20, 27.94\xb10.20, 29.27\xb10.20, 30.07\xb10.20, 30.43\xb10.20, 31.29\xb10.20, 32.25\xb10.20, 34.07\xb10.20, 34.94\xb10.20, 35.53\xb10.20, 36.08\xb10.20, 37.21\xb10.20, 38.17\xb10.20, 39.19\xb10.20, and 9.23\xb10.20.
6. The crystal modification 1 (polymorphic form F) of the mono sodium salt of D-isoglutamyl-D-tryptophan of claim 3, having an XRPD pattern comprising peaks, in terms of 2\u03b8, at: 9.23\xb10.10, 9.91\xb10.10, 12.41\xb10.10, 13.76\xb10.10, 14.87\xb10.10, 15.75\xb10.10, 17.88\xb10.10, 18.78\xb10.10, 19.57\xb10.10, 19.84\xb10.10, 20.31\xb10.10, 21.32\xb10.10, 21.55\xb10.10, 22.95\xb10.10, 23.45\xb10.10, 24.34\xb10.10, 24.96\xb10.10, 27.49\xb10.10, 27.94\xb10.10, 29.27\xb10.10, 30.07\xb10.10, 30.43\xb10.10, 31.29\xb10.10, 32.25\xb10.10, 34.07\xb10.10, 34.94\xb10.10, 35.53\xb10.10, 36.08\xb10.10, 37.21\xb10.10, 38.17\xb10.10, 39.19\xb10.10, and 9.23\xb10.10.
7. The crystal modification 1 (polymorphic form F) of the mono sodium salt of D-isoglutamyl-D-tryptophan of claim 3, having an XRPD pattern measured using a diffractometer (copper anti-cathode) and expressed in terms of inter-planar distances d, Bragg’s angle 2 theta, and relative intensity (expressed as a percentage with respect to the most intense ray) as follows:
2-Theta
D-spacing
Relative Intensity
(\xb0)
(Angstrom)
(%)
9.23
9.573
2
9.91
8.917
41.3
12.41
7.126
37.6
13.76
6.43
0.8
14.87
5.954
35.8
15.75
5.622
7.6
17.88
4.957
5.5
18.78
4.721
58.9
19.57
4.532
30.9
19.84
4.471
28.1
20.31
4.368
2.9
21.32
4.165
53.5
21.55
4.12
30.3
22.95
3.873
67.4
23.45
3.79
24.5
24.34
3.654
19.4
24.96
3.565
85.2
27.49
3.242
100
27.94
3.19
23.3
29.27
3.049
19.1
30.07
2.97
27.2
30.43
2.935
15.2
31.29
2.856
39.9
32.25
2.774
13
34.07
2.629
19.3
34.94
2.566
7.8
35.53
2.525
5
36.08
2.487
8.4
37.21
2.414
15.5
38.17
2.356
9.1
39.19
2.297
3.1
8. The crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan of claim 1, wherein the crystalline material is crystal modification 2 (polymorphic form I).
9. The crystal modification 2 (polymorphic form I) of the mono sodium salt of D-isoglutamyl-D-tryptophan of claim 8 having an XRPD pattern as shown in FIG. 3.
10. The crystal modification 2 (polymorphic form I) of the mono sodium salt of D-isoglutamyl-D-tryptophan of claim 8, having an XRPD pattern comprising peaks, in terms of 2\u03b8, at: 9.65\xb10.20, 10.41\xb10.20, 11.2\xb10.20, 11.71\xb10.20, 13.45\xb10.20, 13.93\xb10.20, 14.44\xb10.20, 15.61\xb10.20, 17.01\xb10.20, 18.18\xb10.20, 18.65\xb10.20, 20.02\xb10.20, 20.85\xb10.20, 21.39\xb10.20, 21.73\xb10.20, 22.52\xb10.20, 23.27\xb10.20, 24.3\xb10.20, 25.84\xb10.20, 26.82\xb10.20, 28.49\xb10.20, 30.18\xb10.20, 30.76\xb10.20, 31.49\xb10.20, 33.03\xb10.20, 34.55\xb10.20, 34.97\xb10.20, 35.74\xb10.20, 37.25\xb10.20, 37.71\xb10.20, and 38.79\xb10.20.
11. The crystal modification 2 (polymorphic form I) of the mono-sodium salt of D-isoglutamyl-D-tryptophan of claim 8, having an XRPD pattern comprising peaks, in terms of 2\u03b8, at: 9.65\xb10.10, 10.41\xb10.10, 11.2\xb10.10, 11.71\xb10.10, 13.45\xb10.10, 13.93\xb10.10, 14.44\xb10.10, 15.61\xb10.10, 17.01\xb10.10, 18.18\xb10.10, 18.65\xb10.10, 20.02\xb10.10, 20.85\xb10.10, 21.39\xb10.10, 21.73\xb10.10, 22.52\xb10.10, 23.27\xb10.10, 24.3\xb10.10, 25.84\xb10.10, 26.82\xb10.10, 28.49\xb10.10, 30.18\xb10.10, 30.76\xb10.10, 31.49\xb10.10, 33.03\xb10.10, 34.55\xb10.10, 34.97\xb10.10, 35.74\xb10.10, 37.25\xb10.10, 37.71\xb10.10, and 38.79\xb10.10.
12. The crystal modification 2 (polymorphic form I) of the mono sodium salt of D-isoglutamyl-D-tryptophan of claim 8, having an XRPD pattern measured using a diffractometer (copper anti-cathode) and expressed in terms of inter-planar distances d, Bragg’s angle 2 theta, and relative intensity (expressed as a percentage with respect to the most intense ray) as follows:
2-Theta
D-spacing
Relative Intensity
(\xb0)
(Angstrom)
(%)
9.65
9.161
5.3
10.41
8.492
23.7
11.20
7.897
40.4
11.71
7.549
4.5
13.45
6.58
90.2
13.93
6.351
15.9
14.44
6.128
3.7
15.61
5.672
32.4
17.01
5.207
9.9
18.18
4.876
11.7
18.65
4.755
47.8
20.02
4.432
59.2
20.85
4.257
35.9
21.39
4.15
24.1
21.73
4.086
27.3
22.52
3.945
100
23.27
3.819
13.7
24.30
3.66
32.4
25.84
3.445
69.5
26.82
3.322
82.5
28.49
3.13
30.1
30.18
2.959
58.8
30.76
2.904
86.9
31.49
2.839
35.3
33.03
2.71
8.7
34.55
2.594
17.8
34.97
2.564
43.4
35.74
2.51
8.5
37.25
2.412
28.1
37.71
2.383
28.5
38.79
2.319
16.9
13. The crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan of claim 1, wherein the crystalline material is crystal modification 3 (polymorphic form X).
14. The crystal modification 3 (polymorphic form X) of the mono sodium salt of D-isoglutamyl-D-tryptophan of claim 13 having an XRPD pattern as shown in FIG. 4.
15. The crystal modification 3 (polymorphic form X) of the mono sodium salt of D-isoglutamyl-D-tryptophan of claim 13, having an XRPD pattern comprising peaks, in terms of 2\u03b8, at: 9.187\xb10.200, 11.058\xb10.200, 11.713\xb10.200, 12.239\xb10.200, 13.785\xb10.200, 14.806\xb10.200, 15.763\xb10.200, 17.126\xb10.200, 17.693\xb10.200, 18.268\xb10.200, 18.562\xb10.200, 19.261\xb10.200, 20.033\xb10.200, 20.63\xb10.200, 21.006\xb10.200, 21.778\xb10.200, 22.268\xb10.200, 23.054\xb10.200, 23.361\xb10.200, 23.851\xb10.200, 24.626\xb10.200, 24.981\xb10.200, 25.507\xb10.200, 26.257\xb10.200, 26.963\xb10.200, 27.329\xb10.200, 27.807\xb10.200, 28.243\xb10.200, 28.975\xb10.200, 29.264\xb10.200, 29.687\xb10.200, 30.409\xb10.200, 30.798\xb10.200, 31.193\xb10.200, 31.724\xb10.200, 32.505\xb10.200, 32.985\xb10.200, 33.645\xb10.200, 34.249\xb10.200, 34.587\xb10.200, 35.048\xb10.200, 35.41\xb10.200, 35.933\xb10.200, 36.833\xb10.200, 37.276\xb10.200, 37.937\xb10.200, 38.467\xb10.200, and 39\xb10.200.
16. The crystal modification 3 (polymorphic form X) of the mono-sodium salt of D-isoglutamyl-D-tryptophan of claim 13, having an XRPD pattern comprising peaks, in terms of 2\u03b8, at: 9.187\xb10.100, 11.058\xb10.100, 11.713\xb10.100, 12.239\xb10.100, 13.785\xb10.100, 14.806\xb10.100, 15.763\xb10.100, 17.126\xb10.100, 17.693\xb10.100, 18.268\xb10.100, 18.562\xb10.100, 19.261\xb10.100, 20.033\xb10.100, 20.63\xb10.100, 21.006\xb10.100, 21.778\xb10.100, 22.268\xb10.100, 23.054\xb10.100, 23.361\xb10.100, 23.851\xb10.100, 24.626\xb10.100, 24.981\xb10.100, 25.507\xb10.100, 26.257\xb10.100, 26.963\xb10.100, 27.329\xb10.100, 27.807\xb10.100, 28.243\xb10.100, 28.975\xb10.100, 29.264\xb10.100, 29.687\xb10.100, 30.409\xb10.100, 30.798\xb10.100, 31.193\xb10.100, 31.724\xb10.100, 32.505\xb10.100, 32.985\xb10.100, 33.645\xb10.100, 34.249\xb10.100, 34.587\xb10.100, 35.048\xb10.100, 35.41\xb10.100, 35.933\xb10.100, 36.833\xb10.100, 37.276\xb10.100, 37.937\xb10.100, 38.467\xb10.100, and 39\xb10.100.
17. The crystal modification 3 (polymorphic form X) of the mono sodium salt of D-isoglutamyl-D-tryptophan of claim 13, having an XRPD pattern measured using a diffractometer (copper anti-cathode) and expressed in terms of inter-planar distances d, Bragg’s angle 2 theta, and relative intensity (expressed as a percentage with respect to the most intense ray) as follows:
2-Theta
D-spacing
Relative Intensity
(\xb0)
(Angstrom)
(%)
9.187
9.618
25.4
11.058
7.995
2.3
11.713
7.549
18.7
12.239
7.226
34.2
13.785
6.419
23.5
14.806
5.978
13
15.763
5.618
5
17.126
5.173
29.3
17.693
5.009
8.4
18.268
4.852
48.2
18.562
4.776
28.2
19.261
4.604
14.3
20.033
4.429
14.5
20.630
4.302
17.2
21.006
4.226
12
21.778
4.078
2.4
22.268
3.989
100
23.054
3.855
6.4
23.361
3.805
7.4
23.851
3.728
1.8
24.626
3.612
14.9
24.981
3.562
14.7
25.507
3.489
11.1
26.257
3.391
34.3
26.963
3.304
11.1
27.329
3.261
20.6
27.807
3.206
35
28.243
3.157
25.6
28.975
3.079
1.1
29.264
3.049
2.3
29.687
3.007
9.5
30.409
2.937
20.9
30.798
2.901
6.1
31.193
2.865
6.9
31.724
2.818
24.7
32.505
2.752
8
32.985
2.713
12.1
33.645
2.662
26.5
34.249
2.616
15.2
34.587
2.591
8.6
35.048
2.558
4.6
35.410
2.533
3.3
35.933
2.497
15.3
36.833
2.438
8
37.276
2.41
10.8
37.937
2.37
12.7
38.467
2.338
14.7
39.000
2.308
2.6
18. The crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan of claim 1, wherein the crystalline material is a mixture of the crystal modification 1 (polymorphic form F) and the crystal modification 2 (polymorphic form I) of the mono sodium salt of D-isoglutamyl-D-tryptophan.
19. The crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan of claim 1, wherein the crystalline material is a mixture of the crystal modification 1 (polymorphic form F) and the crystal modification 3 (polymorphic form X) of the mono sodium salt of D-isoglutamyl-D-tryptophan.
20. The mixture of the crystal modification 1 (polymorphic form F) and the crystal modification 3 (polymorphic form X) of the mono sodium salt of D-isoglutamyl-D-tryptophan of claim 19 having an XRPD pattern as shown in FIG. 9.
21. A process for the preparation of crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan, wherein the process comprises the steps of:
(a) preparing a solution of D-isoglutamyl-D-tryptophan and sodium hydroxide in water at a pH of about 6.5 to about 7.2;
(b) filtering the solution to remove solid particulates;
(c) evaporating the water to concentrate the filtrate; and
(d) adding isopropanol to precipitate the mono-sodium salt of D-isoglutamyl-D-tryptophan,
or
steps (a) and (b) followed by the steps of:
(e) stirring the solid obtained from process steps (a), (b), (c), and (d) with ethyl acetate; and
(f) filtering the solid,
or
steps (a) and (b) followed by the steps of:
(g) evaporating the filtrate from step (b) to give a solid;
(h) adding water to obtain a solution of the mono-sodium salt of D-isoglutamyl-D-tryptophan; and
(i) evaporating the water over a period of more than about 5 hrs to give the mono-sodium salt of D-isoglutamyl-D-tryptophan in crystalline form,
or
(j) preparing a solution of the mono-sodium salt of D-isoglutamyl-D-tryptophan in methanol;
(k) filtering the solution to remove solid particulates; and
(l) adding isopropanol to precipitate the mono-sodium salt of D-isoglutamyl-D-tryptophan,
or
(m) preparing a solution of the mono-ammonium salt of D-isoglutamyl-D-tryptophan and sodium hydroxide in water;
followed by steps (b), (c) and (d).
22. The process of claim 21 comprising steps (a), (b), (c) and (d), wherein the stirring time in step (d) is from about 1.5 to about 16 hours.
23. The process of claim 21 comprising steps (a), (b), (c) and (d), wherein the stirring time in step (d) is about 1 hour.
24. The process of claim 21 comprising steps (a), (b), (c), (d), (e) and (f), wherein the stirring time in step (d) is about 1 hour and the stirring time in ethyl acetate in step (f) is about 2.5 hours.
25. The process of claim 21 comprising steps (a), (b), (g), (h) and (i), wherein about 18 to about 22 ml of water is added in step (h) per gm of the mono-sodium salt of D-isoglutamyl-D-tryptophan and the evaporation time in step (i) is from about 5 to about 6 hours and the temperature of evaporation is from about 30\xb0 C. to about 35\xb0 C.
26. The process of claim 21 comprising steps (j), (k), and (l), wherein the ratio of the mono-sodium salt of D-isoglutamyl-D-tryptophan in step (j) is 1 gm per about 11 to about 13 ml methanol and the ratio of isopropanol to methanol in step (l) is from about 0.4 to about 0.6 ml to 1 ml.
27. The process of claim 21 comprising steps (m), (b), (c) and (d), wherein the stirring time in step (d) is from about 12 hours to about 16 hours.
28. A pharmaceutical composition comprising crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan and at least one pharmaceutically acceptable carrier.
29. (canceled)
30. (canceled)
31. (canceled)
32. (canceled)
33. (canceled)
34. The pharmaceutical composition of claim 28 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is crystal modification 2 (polymorphic form I).
35. The pharmaceutical composition of claim 28 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is crystal modification 3 (polymorphic form X).
36. The pharmaceutical composition of claim 28 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is a mixture of crystal modification 1 (polymorphic form F) and crystal modification 2 (polymorphic form I) of the mono sodium salt of D-isoglutamyl-D-tryptophan.
37. The pharmaceutical composition of claim 28 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is a mixture of crystal modification 1 (polymorphic form F) and crystal modification 3 (polymorphic form X) of the mono sodium salt of D-isoglutamyl-D-tryptophan.
38. A method of medical treatment comprising administering a therapeutically effective amount of crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan to a subject having or suspected of having an auto-immune disease.
39. The method of medical treatment of claim 38 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is crystal modification 2 (polymorphic form I).
40. The method of medical treatment of claim 38 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is crystal modification 3 (polymorphic form X).
41. The method of medical treatment of claim 38 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is a mixture of crystal modification 1 (polymorphic form F) and crystal modification 2 (polymorphic form I) of the mono sodium salt of D-isoglutamyl-D-tryptophan.
42. The method of medical treatment of claim 38 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is a mixture of crystal modification 1 (polymorphic form F) and crystal modification 3 (polymorphic form X) of the mono sodium salt of D-isoglutamyl-D-tryptophan.
43. A method of medical treatment comprising administering a therapeutically effective amount of crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan to a subject having or suspected of having psoriasis.
44. The method of medical treatment of claim 43 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is crystal modification 2 (polymorphic form I).
45. The method of medical treatment of claim 43 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is crystal modification 3 (polymorphic form X).
46. The method of medical treatment of claim 43 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is a mixture of crystal modification 1 (polymorphic form F) and crystal modification 2 (polymorphic form I) of the mono sodium salt of D-isoglutamyl-D-tryptophan.
47. The method of medical treatment of claim 43 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is a mixture of crystal modification 1 (polymorphic form F) and crystal modification 3 (polymorphic form X) of the mono sodium salt of D-isoglutamyl-D-tryptophan.
48. A method of medical treatment comprising administering a therapeutically effective amount of crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan to a subject having or suspected of having atopic dermatitis.
49. The method of medical treatment of claim 48 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is crystal modification 2 (polymorphic form I).
50. The method of medical treatment of claim 48 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is crystal modification 3 (polymorphic form X).
51. The method of medical treatment of claim 48 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is a mixture of crystal modification 1 (polymorphic form F) and crystal modification 2 (polymorphic form I) of the mono sodium salt of D-isoglutamyl-D-tryptophan.
52. The method of medical treatment of claim 48 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is a mixture of crystal modification 1 (polymorphic form F) and crystal modification 3 (polymorphic form X) of the mono sodium salt of D-isoglutamyl-D-tryptophan.
53. A method of medical treatment comprising administering a therapeutically effective amount of crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan to a subject having or suspected of having rheumatoid arthritis.
54. The method of medical treatment of claim 53 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is crystal modification 2 (polymorphic form I).
55. The method of medical treatment of claim 53 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is crystal modification 3 (polymorphic form X).
56. The method of medical treatment of claim 53 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is a mixture of crystal modification 1 (polymorphic form F) and crystal modification 2 (polymorphic form I) of the mono sodium salt of D-isoglutamyl-D-tryptophan.
57. The method of medical treatment of claim 53 wherein the crystalline mono-sodium salt of D-isoglutamyl-D-tryptophan is a mixture of crystal modification 1 (polymorphic form F) and crystal modification 3 (polymorphic form X) of the mono sodium salt of D-isoglutamyl-D-tryptophan.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A device for transmitting an audio stream separately from a video stream, comprising:
an input operative to receive a service provider signal;
a first tuner operative to receive the service provider signal from the input and configured to generate a first signal;
a first demodulator accepting the first signal from the first tuner and configured to generate a first audio signal and first video signal from the first signal;
a second tuner operative to receive the service provider signal from the input and configured to generate a second signal;
a second demodulator accepting the second signal from the second tuner and configured to generate a second audio signal and second video signal from the second signal;
an enclosure surrounding at least the first tuner, second tuner, the first demodulator, and the second demodulator;
a first output from the enclosure, the first output operative to transmit the first audio signal and the first video signal;
a second output from the enclosure, the second output operative to transmit the second video signal;
third output from the enclosure, the third output operative to transmit the second audio signal; and
a module located externally of the enclosure and connected to the third output, the module operative to receive the second audio signal and to convert the second audio signal into a wireless signal.
2. The device of claim 1, further comprising a user input, the user input operative to change a frequency of at least the second audio signal.
3. A method for transmitting at least a first and second audio signal, comprising:
transmitting the first audio signal to a first device;
transmitting a first video signal to the first device, the first video signal associated with the first audio signal;
transmitting the second audio signal to a second device;
transmitting a second video signal to the first device, the second video signal associated with the second audio signal;
receiving a command to adjust the second video signal relative to the first video signal;
in response to receiving the command, transmitting the second audio signal to the first device; and
further in response to receiving the command, transmitting the first audio signal to the second device.
4. The method of claim 3, further comprising stripping the second audio signal from the second video signal prior to transmitting either the second audio signal or the second video signal.
5. The method of claim 3, wherein prior to receiving the command to adjust the second video signal relative to the first video signal, the method further comprising:
displaying the first video signal on a first screen area of the first device; and
displaying the second video signal on a second screen area of the first device.
6. The method of claim 5, wherein in response to receiving the command to adjust the second video signal relative to the first video signal, the method further comprising:
switching the first video signal to display on the second screen area of the first device; and
switching the second video signal to display on the first screen area of the first device.
7. The method of claim 6, wherein the first screen area surrounds the second screen area.
8. The method of claim 6, wherein at least one of the first and second audio signals are wirelessly transmitted.
9. The method of claim 3, wherein the second audio signal cannot be perceived without the second device.
10. The method of claim 3, wherein all transmissions are performed by a third device.
11. The method of claim 10, wherein the third device is a set-top box.
12. A method for transmitting information, comprising:
providing a first video signal for display on a first screen area of a first device;
providing a second video signal for display on a second screen area of the first device;
providing a first audio signal to the first device;
providing a second audio signal to a second device;
receiving an audio toggle command;
in response to receiving the audio toggle command, providing the second audio signal to the first device; and
further in response to receiving the audio toggle command, providing the first audio signal to the second device.
13. The method of claim 12, further comprising:
generating the first video signal and the first audio signal; and
generating the second video signal and the second audio signal.
14. The method of claim 13, wherein the operation of separating the second set of information comprises:
receiving the second set of information as a single signal including both the second video signal and second audio signal modulated together; and
demodulating the second video signal from the second audio signal.
15. The method of claim 14, wherein the second format is a radio frequency.
16. The method of claim 13, wherein:
the second audio signal is converted from a first format to a second format; and
the second audio signal is provided to the second device in the second format.